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MyD88 is an essential component of retinoic
acid-induced differentiation in human pluripotent
embryonal carcinoma cells
Gomaa Sulaiman1,2,11, Aoife Cooke1,2,11, Brendan Ffrench1,2, Claudia Gasch1,2, Olayemi Azeez Abdullai1,2, Kevin O’Connor1,2,
Salah Elbaruni1,2, Gordon Blackshields1, Cathy Spillane1,2, Helen Keegan1,2, Victoria McEneaney1,2, Ronan Knittel1,2,
Annamarie Rogers3, Ian B Jeffery4, Brendan Doyle1,2, Mark Bates1, Charles d’Adhemar1,2, Mathia YC Lee5, Eric L Campbell6,
Paul N Moynagh7,6, Desmond G Higgins8, Sharon O’Toole1,9, Luke O’Neill10, John J O’Leary1,2 and Michael F Gallagher*,1,2
We have previously reported that myeloid differentiation primary response gene 88 (MyD88) is downregulated during all-trans
retinoic acid (RA)-induced differentiation of pluripotent NTera2 human embryonal carcinoma cells (hECCs), whereas its maintained
expression is associated with RA differentiation resistance in nullipotent 2102Ep hECCs. MyD88 is the main adapter for toll-like
receptor (TLR) signalling, where it determines the secretion of chemokines and cytokines in response to pathogens. In this study,
we report that loss of MyD88 is essential for RA-facilitated differentiation of hECCs. Functional analysis using a specific MyD88
peptide inhibitor (PepInh) demonstrated that high MyD88 expression in the self-renewal state inhibits the expression of a specific
set of HOX genes. In NTera2 cells, MyD88 is downregulated during RA-induced differentiation, a mechanism that could be broadly
replicated by MyD88 PepInh treatment of 2102Ep cells. Notably, MyD88 inhibition transitioned 2102Ep cells into a stable, self-
renewing state that appears to be primed for differentiation upon addition of RA. At a molecular level, MyD88 inhibition combined
with RA treatment upregulated HOX, RA signalling and TLR signalling genes. These events permit differentiation through a
standard downregulation of Oct4-Sox2-Nanog mechanism. In line with its role in regulating secretion of specific proteins,
conditioned media experiments demonstrated that differentiated (MyD88 low) NTera2 cell media was sufficient to differentiate
NTera2 cells. Protein array analysis indicated that this was owing to secretion of factors known to regulate angiogenesis,
neurogenesis and all three branches of TGF-β Superfamily signalling. Collectively, these data offer new insights into RA controlled
differentiation of pluripotent cells, with notable parallels to the ground state model of embryonic stem cell self-renewal. These data
may provide insights to facilitate improved differentiation protocols for regenerative medicine and differentiation-therapies in
cancer treatment.
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Pluripotent stem cells have great regenerativemedicine potential
owing to their ability to differentiate into tissues representative
of all three germ layers.1–3 Pluripotency remains imprecisely
characterised, particularly the events upstream of the key
regulatory trio Oct4, Sox2 and Nanog. It has been reported
that pluripotent embryonic stem cells (ESCs) transition from a
naive ‘ground state’ through primed states towards commitment
to various specific lineages.4-6 This process appears to be tightly
regulated by the presence of specific growth factors within the
niche, particularly those regulating the three branches of
TGF-β Superfamily (BMP, TGF-β and activin) signalling.7,5
Harnessing the power of pluripotent stem cells requires an
improved understanding of this regulatory mechanism.
As they are more stable in culture than human ESCs
(hESCs) or induced pluripotent stem cells (iPSCs), human
embryonal carcinoma cells (hECCs) are a useful tool for the
elucidation of pluripotent mechanisms.8-11We have previously
reported that myeloid differentiation response gene 88
(MyD88) expression is downregulated during retinoic acid
(RA)-induced differentiation of pluripotent NTera2 hECCS but
maintained in RA-treated nullipotent 2102Ep hECCs.12 The
RA signalling pathway initially involves recognition and
translocation of retinoids by cell surface receptor STRA6
(Stimulated by RA6), followed by translocation through the cell
via Cellular Retinoid and Cellular Retinoic Acid Binding
Proteins (CRBPs & CRABPs). Subsequently, RA binds to
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Figure 1 Loss of MyD88 facilitates RA-induced differentiation of a sub-population of 2102Ep cells. 2102Ep cells were treated with MyD88 PepInh for 24 h and then with
MyD88 PepInh+RA (refreshed daily) for an additional 11 days. After these 12 days treatment, cellular morphology was found to be unaltered in control cells (a: −RA, b: +RA,
c: control PepInh −RA, d: control PepInh +RA e: MyD88 Pepinh-RA. All × 10 magnification), suggesting that these cells remained undifferentiated. In contrast, the majority of
cells grown in MyD88 PepInh+RA conditions demonstrated a differentiated morphology (f). This was supported by cell count data indicating a substantial, significant decrease in
MyD88 PepInh+RA-treated cells compared with controls (g) but was contradicted by similar levels of pluripotency marker AP measured by quantitative ELISA (h). These samples
were harvested and their differentiation status confirmed through qPCR analysis of Oct4, Sox2 and Nanog levels (i), which indicated that the levels of these pluripotency markers
had not decreased in MyD88 PepInh+RA cells sufficiently to indicate typical hECC differentiation based on our typical data.45 Finally, 24 h treatment with the MyD88 PepInh was
shown to result in a statistically significant decrease in phospho-IκB expression as measured by quantitative ELISA following treatment with Interleukin-1β, indicating a decrease
in MyD88-dependent TLR signalling (j). Together, these data led to a hypothesis that MyD88 PepInh+RA samples contain two sub-populations, one differentiated and one
nullipotent, the testing of which is described in Figure 2. *P-valueo 0.05; **P-valueo0.01
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nuclear RA and Retinoid X Receptors (RARs & RXRs), which
facilitate regulation of targets such as HOX genes and Oct4-
Sox2-Nanog.13-16 MyD88 is best known for its role as the main
adapter protein for toll-like receptor (TLR) signalling, a key
component of innate immunity.17-19 In response to detection
of specific pathogens, MyD88-dependent TLR signalling
activates NF-κB. Alternatively, MyD88-independent TLR
signalling results in activation of type 1 interferons, which act
through interferon-stimulated genes (ISGs) and JAK-STAT
signalling.18,19 Each mechanism results in secretion of
Figure 2 Inhibition of MyD88 facilitates RA-induced differentiation of 2102Ep cells. 2102Ep cells were treated with MyD88 PepInh for 24 h and then with MyD88 PepInh+RA
(refreshed daily) for an additional 11 days. Cells from three independent replicates were assessed via flow cytometry (a) for differentiation status using pluripotency marker
SSEA4. (a) Open lines represent negative staining controls for each sample. Filled lines represent the stained sample. Green represents the SSEA4Neg cells and red the
SSEA4Pos cells, as determined by internal negative staining controls. 2102Ep cells were shown to be almost completely SSEA4Pos in –RA conditions (a–i) and 62.00± 11.86%
SSEA4Neg when force differentiated using a siRNA knockdown of Sox2 protocol we have previously described (a–ii),45 differences that were found to be statistically significant (b).
Cells grown in control PepInh –RA (a–iii), MyD88 PepInh –RA (a–iv) and control PepInh +RA (a–v) conditions were found to remain almost completely SSEA4Pos (a–iii–v: c–d,
statistical analysis). In contrast, cells grown in MyD88 PepInh+RA conditions for 12 days were found to be ~ 1:1 SSEA4Pos:SSEA4Neg (a–vi: d, statistical analysis). Although this
was initially thought to suggest the presence of two sub-populations, additional experiments (Supplementary Data 4) suggest that this is owing to a small population of cells that
persist through RA treatment, which can proliferate to a sizable populations over this time-scale. SSEA4Pos and SSEA4Neg populations (a–vi) were isolated via FACS and shown
by qPCR to express Oct4-Sox2-Nanog at high and low levels respectively (e). Collectively, this indicates a model (f) where 2102Ep cells can be transitioned to a stable, apparently
primed self-renewal (SRPR) state when MyD88 is consistently inhibited, a state that can be differentiated by RA. *P-valueo 0.05; **P-valueo0.01
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specific chemokines and cytokines, which facilitate an
immune response.20,21 A relationship between MyD88 and
pluripotency has not been previously described.
Here, we report that loss of MyD88 is a key component of
RA-induced differentiation in hECCs. Mechanistically, MyD88
promotes self-renewal through inhibition of HOX and RA
signalling pathway gene expression, while its loss facilitates
transition to an alternative self-renewal state that is primed for
RA-induced differentiation through the standard downregula-
tion of Oct4-Sox2-Nanog mechanism. Functionally, condi-
tioned media experiments demonstrated that factors secreted
by differentiated (low MyD88) cells were sufficient to force
differentiation of NTera2 cells. When characterised, these
proteins were identified as known regulators of all three
branches of TGF-β Superfamily signalling, as well as
angiogenesis and neurogenesis. Collectively, these data
provide new insights in to the mechanisms involved in early
differentiation of pluripotent hECCs.
Results
MyD88 is sufficient to maintain the self-renewal state and
its loss necessary for RA differentiation. We screened
early time-point data from a RA differentiation experiment and
identified MyD88 as a potential upstream regulator of Oct4-
Sox2-Nanog (Supplementary Data 1–3).12 Hypothesising
that loss of MyD88 may be necessary for RA differentiation
of hECCs, nullipotent 2102Ep cells were treated with a
MyD88 peptide inhibitor (PepInh), which was refreshed daily,
in combination with RA. Measurement of phosphorylated-I-κ-
B-α expression in response to Interleukin-1β (IL-1β) indicated
that MyD88-dependent TLR signalling was significantly
decreased by MyD88 PepInh treatment (Figure 1j). The
morphology and cellular proliferation characteristics of
MyD88 PepInh+RA-treated (12 days) cells suggested differ-
entiation, a response that was not observed in cells treated
with MyD88 PepInh-RA or control PepInh±RA (Figures 1a–f).
Cells treated with MyD88 PepInh+RA showed a substantial
decrease in cellular proliferation compared with cells treated
with control PepInh+RA, which was also suggestive of
differentiation (Figure 1g). Notably, MyD88 PepInh-treated
cells did not spontaneously differentiate, whereas withdrawal
of the MyD88 PepInh rendered cells resistant to RA
(reversion to nullipotency). This indicates a mechanism
where consistent inhibition of MyD88 transitions 2102Ep
cells into a new, stable self-renewal state that is now primed
for differentiation in response to RA. Flow cytometry analysis
of the expression of pluripotency marker stage specific
embryonic antigen 4 (SSEA4) on individual cells demon-
strated the presence of approximately equal numbers of self-
renewing (SSEA4Pos) and differentiated (SSEA4Neg) cells
after 12 days MyD88 PepInh+RA treatment (Figures 2a–d). In
line with this, cells harvested at the end of this experiment
showed expression of pluripotency markers alkaline phos-
phatase (AP, Figure 1h) and Oct4, Sox2 and Nanog
(Figure 1i) suggestive of a mixed population. However, when
separated by FACS, SSEA4Pos and SSEA4Neg cells were
found to express high and low levels of Oct4, Sox2 and
Nanog respectively (Figure 2e), confirming the undifferentiated
and differentiated states of these 2 cell types. These data
indicate a model where loss of MyD88 is necessary for
RA-induced differentiation of 2102Ep cells. Mechanistically,
loss of MyD88 transitions the majority of 2102Ep cells to
what appears to be a stable, primed self-renewal (SRPR)
state, which facilitates differentiation upon addition of RA
(Figure 2f).
At first glance, the presence of a large, undifferentiated sub-
population after 12 days treatment (Figure 2a) suggested the
presence of two sub-populations within the 2102Ep model.
However, it must be noted that a small population of rapidly
proliferating undifferentiated cells substantially expand over
time compared with slow or non-proliferating differentiated
cells. With this in mind, in RA-treated NTera2 cells, we
detected a small, persistent undifferentiated population, both
in culture and in vivo xenografts, which could substantially
expand over time (Supplementary Data 4). As such, the
undifferentiated cells may represent a lack of complete
efficiency in hECC differentiation protocols rather than a
distinct sub-population.
As these data indicated that loss of MyD88 was required for
RA-induced differentiation of 2102Ep cells, we next hypothe-
sised that MyD88 might be sufficient for maintenance of the
pluripotent NTera2 self-renewal state. Testing this, MyD88was
overexpressed in NTera2 cells using a constitutive expression
plasmid, and then challenged with RA. When treated with RA,
cells overexpressing MyD88 (Figures 3a and b) retained
substantially higher levels of pluripotency markers AP
(Figure 3c), Oct4 and Nanog (Figure 3d) compared with RA-
treated control cells. Collectively, these data indicate that
MyD88 is sufficient to maintain the self-renewal state and its
loss necessary for RA differentiation. In addition, inhibition of
MyD88 can be used to generate what appears to be a stable
self-renewal state that is primed for RA differentiation.
A potential role for MyD88 in mesodermal differentiation
of 2102Ep cells. Once it had been shown that loss of MyD88
was necessary for RA differentiation, we assessed whether
loss of MyD88 facilitated non-RA lineage differentiation
mechanisms. As specific lineage differentiation protocols
have not been previously optimised for hECCs, commercially
available early lineage differentiation commitment kits were
used. These protocols are useful indicators of initiation of
differentiation, but further lineage-specific protocols are
required for complete differentiation. Although the exact
content of the growth factor mixes supplied with these kits
is not released, the supplier confirmed for us that none
contained RA. 2102Ep cells were treated with and without the
MyD88 PepInh for 24 h as before and then treated with
specific differentiation protocols for each lineage. Differentia-
tion was then assessed as changes in morphology, and loss
of SSEA4 and Oct4-Sox2-Nanog expression. This analysis
suggested that the mesoderm differentiation kit could replace
RA in the MyD88 inhibited mechanism observed previously
(Figures 4a–i). The strongest evidence for this is the obvious
difference in morphology observed in cells treated with
MyD88 PepInh+mesoderm kit but not control cells
(Figures 4e and f). This is in line with previous reports linking
RA and mesodermal differentiation of mES cells.22,23 How-
ever, although the mesoderm kit-only control had no effect on
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morphology (Figure 4e), flow cytometry using SSEA4
revealed two populations with only a small, statistically
significant difference compared with MyD88 PepInh+kit
(Figures 4g and h). In contrast, the ectoderm differentiation
protocol resulted in the production of an SSEA4Neg sub-
population that was too small to convincingly suggest a
functional differentiation mechanism (Figures 4g, l and m).
The endoderm differentiation protocol did not result in the
differentiation of any 2102Ep cells (Figures 4g, j and k).
These morphology results suggest that MyD88 regulation is
not RA-specific and may have a role in mesoderm differ-
entiation, but further studies are required to confirm this.
Differentiated NTera2 cells secrete factors sufficient for
differentiation. The main known role of MyD88 is in TLR
Signalling, where it determines the profile of factors secreted
by the cell in response to specific stimuli. Addressing this, we
next undertook a conditioned media experiment to assess
whether self-renewing (high MyD88) and differentiated (low
MyD88) hECCs secrete a different set of factors that influence
their stem cell status. Owing to the nullipotent status of the
2102Ep cells, NTera2 cells were primarily used in this
conditioned media analysis. We first established that NTera2
cells remain terminally differentiated following 7 days RA-free
treatment, even when RA is withdrawn (Supplementary Data
4). Differentiated NTera2 cells could thus be grown in RA-free
media, which could be conditioned with factors secreted by
differentiated cells without RA contamination. Conditioned
media collected for either 7 or 14 days from undifferentiated
(‘UndiffCon’) and differentiated (‘DiffCon’) NTera2 cells was
added to NTera2 cells daily for 7 days. Based on their
subsequent expression of SSEA4, Oct4, Sox2 and Nanog,
treatment of NTera2 cells with DiffCon (collected for 7 or
14 days) media was found to be sufficient to induce
differentiation of NTera2 cells (Figures 5a–c). In contrast,
UndiffCon media did not induce statistically significant
changes in SSEA4, Oct4, Sox2 or Nanog expression
(Figures 5a–c). Interestingly, it was noted that DiffCon media
could replace RA in the MyD88 PepInh protocol described
earlier (data not shown). Collectively, these data indicate that
differentiated NTera2 cells secrete factors that self-promote
their differentiated state. As MyD88 is a key determinant of the
profile of factors secreted by cells generally, and is differen-
tially expressed in these cell states, it is likely that MyD88 is
involved in this microenvironment regulation mechanism.
Self-renewing, MyD88 Inhibited, RA-treated and differ-
entiated hECCs secrete specific protein profiles. We next
used chemokine–cytokine arrays to characterise some of the
factors contained in UndiffCon and DiffCon media as well as
media conditioned by 2102Ep cells treated with RA or a small
interfering RNA targeting MyD88 (‘siMyD88’, Supplementary
Data 5). Self-renewing NTera2 cells were found to secrete
a specific set of proteins that are known regulators of
angiogenesis and neurogenesis, and follistatin, a known
inhibitor of the Activin signalling (Table 1, Supplementary
Data 5). Treatment of 2102Ep cells with either RA or siMyD88
resulted in specific secretion of different sets of angiogenesis
regulators (Table 1, Supplementary Data 5). Assessment of
DiffCon media indicated secretion of a large set of factors
including known regulators of neurogenesis, TGF-β, Activin
and BMP signalling, and immunity (Table 1, Supplementary
Data 5). Together, this indicates a mechanism where hECC
differentiation is associated with activation of angiogenic and
neurogenic differentiation as well as all three branches of
TGF-β Superfamily signalling. We have shown above that
these are sufficient to differentiate NTera2 cells.
Loss of MyD88 facilitates upregulation of HOX genes and
activation of RA Signalling. We next characterised the
MyD88 molecular mechanism using whole-genome gene
expression array analysis. Initially, 2102Ep cells treated with
MyD88 PepInh or control PepInh ±RA were assessed to
establish events regulated by RA or loss of MyD88
specifically. Subsequently, differentiated SSEA4Neg cells
isolated at the end of the 12 day MyD88 PepInh +RA protocol
Figure 3 MyD88 overexpression inhibits RA differentiation of NTera2 cells.
MyD88 was overexpressed (4 days) in NTera2 cells using a constitutive expression
plasmid. Overexpression of MyD88 was confirmed by qPCR (a: P= 0.004) and
western blot (b) compared with empty plasmid and transfection reagent only controls
(Ctrl) respectively. (c) The expression of pluripotency marker Alkaline Phosphatase
(AP) as measured by quantitative ELISA was significantly decreased in non-
transfected control (NTC) cells treated with RA (4 days) compared with –RA-treated
NTC cells. In contrast, cells overexpressing MyD88 (OEMyD88) showed similar
expression of AP in ±RA conditions. (d) qPCR analysis of these samples
demonstrated that Oct4 (P= 0.004) and Nanog (P= 0.02) expression was not
downregulated in MyD88OE+RA cells in a fashion observed for NTC+RA cells (Sox2
is lower in MyD88OE+RA cells, P= 0.03). These data indicate that maintained
expression of MyD88 is sufficient to inhibit RA-induced differentiation of NTera2 cells.
*P-valueo 0.05; **P-valueo0.01
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were assessed to establish downstream events. All samples,
including SSEA4Pos and MyD88 PepInh+RA controls, passed
quality controls, separated well and showed strong clustering
(Figures 6a and b, full genelists in Supplementary Data 6).
Confirming differentiation, SSEA4Neg cells were found to
downregulate pluripotency markers (Oct4, Sox2, Nanog, Alpl,
Gdf3, Tdgf1, Tert, Esrrb, Myc, Sall4, Thap11, Utf1 and Zfp42)
and upregulate differentiation markers (Mesoderm: Hand1
and Msx1, Definitive Endoderm: Gata6, Cardiac Progenitor:
Isl1, Early Smooth Muscle: Acta2, Haematopoietic Stem Cell/
Early Endothelial Cells: Gata2, Mesenchymal Stem Cells:
CD44 and Eng) compared with SSEA4pos cells. In overview,
while distinct sets of genes were altered by treatment with
MyD88 PepInh or RA, differentiation requires their combina-
tion (Figure 6c). MyD88 inhibition resulted in alteration of 414
genes (119 Up, 295 Down) related to differentiation/embryo-
nic development (Supplementary Data 6&7). Analysis of
molecular relationships via the online tool DAVID24
highlighted the primary effect of MyD88 inhibition as
upregulation of four HOX genes and inhibition of five
Olfactory Receptor (OR) genes and seven taste receptor
type 2 (T2Rs) genes (Table 2). These sensory receptor genes
have, in recent years, been shown to be expressed in non-
sensory tissue such as testis, where they clearly perform a
non-sensory role.25,26 The relationship between RA treat-
ment and the alteration of HOX and OR genes is long
established. However, this is the first description of their
involvement in a MyD88-dependent pre-RA treatment
mechanism. MyD88 inhibition alone did not result in
substantial changes in Oct4, Sox2 or Nanog, RA or TLR
Signalling gene expression, which suggests that MyD88
inhibited cells are in a pluripotent/nullipotent state in which
MyD88-independent TLR signalling has not been activated.
Comparison of control PepInh versus control PepInh+RA
treatment indicated that RA resulted in alteration of only 71
genes (47 Up, 24 Down) including upregulation of RA
Signalling (RarB, Crabp1) and additional HOX (A1, A2, A4,
B1) genes (Table 2, Figure 6c).
Analysis of the 3491 genes (1697 Up, 1794 Down) altered in
SSEA4Neg cells (compared with MyD88 PepInh-treated cells)
highlighted loss of Oct4, Sox2 and Nanog expression as well
as upregulation of additional RA Signalling (Stra6, Crabp2,
RarA and further upregulation of RarB) and HOX (B3, C8, C13
and further upregulation of A1 and A2) genes, all of which are
Figure 4 A potential role for MyD88 in mesodermal differentiation of 2102Ep cells. 2102Ep cells were treated with specific endoderm, mesoderm and ectoderm differentiation
kits to assess whether the MyD88 mechanism was RA-specific. Morphology images show 2102Ep cells stimulated to differentiate down endoderm (a, b), ectoderm (c, d) or
mesoderm (e, f) lineages using specific differentiation kits following treatment with (d–f) or without (a–c) MyD88 PepInh. Differentiation was only apparent in cells treated with the
MyD88 PepInh and then a mesodermal differentiation protocol (f). Cells were subsequently assessed for differentiation status using SSEA4 flow cytometry and Oct4-Sox2-Nanog
qPCR expression levels (g–m). (g) Open lines represent negative staining controls for each sample. Filled lines represent the stained sample. Green represents the SSEA4Neg
cells and red the SSEA4Pos cells, as determined by the internal negative staining controls (i: untreated control, ii: mesoderm kit only, iii: MyD88 PepInh+mesoderm kit, iv: ectoderm
kit only, v: MyD88 PepInh+ectoderm kit, vi: endoderm kit only, vii: MyD88 PepInh+endoderm kit). This analysis indicated that 2102Ep cells treated with MyD88 PepInh+mesoderm
protocol produce a population of SSEA4Neg cells (a-iii: 38.51± 2.1%) that was significantly larger (h) than observed in control cells (a-ii: 15.54± 1.15%). Post-FACS isolation
qPCR analysis of Oct4-Sox2-Nanog confirmed that these were differentiating cells (i). Cells treated with MyD88+ectoderm protocol produced a significant (a-iv: 3.66± 0.13%;
a-v: 13.63± 0.08%; j statistical analysis, k: qPCR) SSEA4Neg population that was insufficient in size to isolate by FACS for qPCR analysis (k). Treatment of cells with the
endoderm protocol did not result in differentiation (a-vi: 2.08± 0.08%; a-vii: 5.43± 0.07%; l: statistical analysis,m: qPCR). Morphology data indicate a potential role for MyD88 in
mesodermal differentiation. *P-valueo 0.05
MyD88 facilitates differentiation of pluripotent cells
G Sulaiman et al
1980
Cell Death and Differentiation
characteristics of RA-induced differentiation of hECCs
(Table 2, Figure 6c). Further mining of the genelist identified
several changes indicative of a switch to MyD88-independent
TLR Signalling, including downregulation of Tlr4 and upregu-
lation of Tlr3 and Tlr7 (24 fold) expression, as well as
upregulation of 16 ISGs and a small number of JAK-STAT
signalling genes, none of which are altered in cells treated with
MyD88 PepInh or RA alone (Table 2, Supplementary Data 6).
Interestingly, loss of OR and T2R expression following MyD88
inhibition appears to be rescued in SSEA4Neg cells. In
summary, these data indicate that, in self-renewing cells,
MyD88 functions to prevent differentiation by inhibiting and
promoting the expression of HOX and OR/T2R genes
respectively. The combination of MyD88 inhibition and RA
leads to differentiation of 2102Ep cells via activation of RA and
MyD88-independent TLR signalling, downregulation of Oct4-
Sox2-Nanog, and upregulation of HOX genes, as illustrated in
Figure 6c.
Discussion
An improved understanding of the mechanisms that regulate
the early differentiation of pluripotent cells is required. In this
study, we report that MyD88 is an essential component of
hECC pluripotency, which must be downregulated to facilitate
RA-induced differentiation. At a molecular level, high MyD88
Figure 5 Differentiated NTera2 cells secrete specific protein profiles sufficient to promote differentiation. Undifferentiated NTera2 cells were grown for 7 days in media
conditioned by (collected for 7 or 14 days) undifferentiated (UndiffCon) or pre-differentiated (DiffCon) NTera2 cells, after which SSEA4 expression levels were assessed using flow
cytometry (a). Open lines represent negative staining controls for each sample. Filled lines represent the stained sample. Green represents the SSEA4Neg cells and red the
SSEA4Pos cells, as determined by internal negative staining controls (a–i: −RA & a–ii: +RA controls). Treatment with DiffCon media (collected for 7 (v) or 14 (vi) days) was found
to reduce SSEA4 expression levels, data that were found to be statistically significant (b). This was accompanied by statistically significant decreases in qPCR measured levels of
Oct4-Sox2-Nanog expression (c, 7 day DiffCon). In contrast, UndiffCon media (collected for 7 (iii) or 14 (iv) days) had no effect on SSEA4 expression (a, b). No statistically
significant changes in qPCR measured levels of Oct4-Sox2-Nanog expression were observed for UndiffCon media (c).These data indicate that differentiated cells secrete factors
that promote differentiation. *P-valueo 0.05; **P-valueo0.01, ns= not significant
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Table 1 Selected proteins secreted by self-renewing (UndiffCon media) and differentiated (DiffCon media) NTera2 cells and 2102Ep cells treated with RA or siMyD88
Protein concentration (pg/ml)
Protein UndiffCon media DiffCon media D-U
Name Mean Std dev Mean Std dev
Activin signalling
Follistatin 44292.86 4544.368 10430.15 3573.709 − 33862.7
Angiogenesis
VEGF R1 24627.48 2956.096 5397.449 1219.654 −19230
MMP-10 299.4709 27.02792 146.45 32.6487 − 153.021
Neurogenesis
NT-3 5876.439 893.9806 631.0113 146.8414 −5245.43
Protein concentration (pg/ml)
Proten −RA media +RA Media
Name Mean Std dev Mean Std dev +RA/−RA
Angiogenesis
VEGF R1 1219.647 366.9537 2836.053 609.5548 1616.406
ANG 573.6194 102.6707 1126.777 157.2161 553.1579
VEGF-C 0 0 39.91538 13.6252 39.91538
Protein concentration (pg/ml)
Protein siMyD88 media siNeg media siMyD88
Name Mean Std dev Mean Std dev /siNeg
ANGPTL4 145179 16072.86 125795.6 6584.325 19383.38
EG-VEGF 19641.05 3632.987 10761.95 1437.177 8879.106
Galectin-7 4685.881 607.541 2865.377 813.5484 1820.503
Protein concentration (pg/ml)
Protein UndiffCon media DiffCon media U-D
Name Mean Std dev Mean Std dev
TGF-beta superfamily signalling
Activin A 0 0 1493.208 200.2996 1493.208
BMP-7 910.8463 440.5303 7208.248 313.3619 6297.402
TGF-β2 0 0 429.1639 71.34182 429.1639
Angiogenesis
EG-VEGF 2273.699 169.0277 8875.279 1347.141 6601.58
Angiostatin 795.0404 260.3674 3859.508 363.6226 3064.468
ANG 190.0116 34.46092 1084.585 109.8753 894.5736
ANG-1 27.52681 25.12288 792.2876 187.0824 764.7608
VEGF-C 0 0 147.6324 31.38247 147.6324
Neurogenesis
NSE 14204.94 3158.078 103668.5 9636.743 89463.53
NT-4 914.8534 422.1725 3853.056 351.035 2938.203
Pluripotency signalling
DKK-1 168.5883 146.0253 3178.466 1009.651 3009.878
Immunity
IL-13 R1 0 0 5847.221 1507.052 5847.221
IL-2 Rb 29.13075 50.45594 1697.817 427.5385 1668.686
IL-13 R2 0 0 1159.137 301.3806 1159.137
IL-23 0 0 673.288 211.3631 673.288
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expression appears to inhibit functional activation of HOX
gene expression to promote the SR state, while its loss
facilitates activation of RA signalling, leading to differentiation
driven by loss of Oct4-Sox2-Nanog. During RA-induced
differentiation, loss of MyD88 forms part of an overall
differentiation mechanism that is associated with the secretion
of a specific set of proteins, which appears to be due to
activation of MyD88-independent TLR signalling. These
secreted proteins include known promoters of all three
branches of TGF-β Superfamily signalling, angiogenesis and
neurogenesis, and are sufficient to facilitate differentiation.
Although these data require further functional validation, a
proposed integrated model of pluripotent hECC RA differ-
entiation is offered in Figure 7.
The pluripotent state is primarily determined by the
presence of regulatory growth factors in the niche.7,3 The
highlighting of MyD88 in this study, which determines the
profile of many proteins secreted by the cell, matches this
model. In particular, pluripotency/differentiation is regulated by
all three branches of TGF-βSuperfamily signalling.7,3 As such,
our demonstration that MyD88 regulates hECC pluripotency
and hECC secretion of regulators of all three branches of TGF-
β Superfamily signalling also matches this model. Specifically,
hECCs appear to use self-secreted proteins to inhibit Activin
signalling in the SR state before promoting differentiation
though activation of BMP and TGF-β signalling. Continuing
these similarities, it is notable that a SR state that appears to
be primed for RA (neural lineage) differentiation can be
generated throughMyD88 inhibition in 2102Ep cells. This is an
interesting parallel to the primed state model of ESC
pluripotency. Although it is important to note that this is a
malignant, and thus clearly mutated, model of pluripotency,
the mechanisms revealed here, or similar non-malignant
mechanisms, may prove useful for exploitation in the hESC
or iPSC field. For example, it may be possible to exploit the
MyD88 mechanism described here, or similar mechanisms, to
generate primed pluripotent cells whose differentiation can be
better controlled. However, it is known that there are many key
differences between murine and human pluripotency: we note
that MyD88 knockout mice appear to have no non-immunity
related defects,20,27-29 suggesting that MyD88 is not an
essential regulator of the mammalian SR state. As such,
collectively our data indicates that MyD88 is a redundant
regulator of mammalian pluripotency, specific regulator of
human pluripotency, or specific regulator of human malignant
pluripotency. As inhibition/knockdown of MyD88 has not been
performed in hESCs to our knowledge, these questions
remain open.
Figure 6 Gene expression array analysis of the MyD88 inhibition facilitated RA differentiation mechanism. Whole-genome gene expression array analysis of the following
samples (n= 3) was undertaken: control PepInh-RA (Ctrl), control PepInh +RA (Ctrl_RA), MyD88 PepInh –RA (MyD), MyD88 PepInh +RA (MyD_RA) and post-experiment
isolated SSEA4Pos (SSEA4Pos) and SSEA4Neg (SSEA4Neg) 2102Ep cells. All biological replicates clustered well and all samples separated well (a, b). Selected genelists for
MyD88 PepInh versus control PepInh, control PepInh-RA versus control PepInh+RA, and SSEA4Neg versus MyD88 PepInh comparisons are shown in Table 2 (full genelists in
Supplementary Data 6). Together, the data reveal an overall mechanism (c) where RA or MyD88 PepInh treatment of self-renewing (SR) cells results in the upregulation of
selected RA and HOX genes, whereas loss of MyD88 is also associated with downregulation of taste family 2 and olfactory receptor (T2R, OR) genes. RA treatment following
MyD88 PepInh treatment results in activation of RA and MyD88-independent TLR signalling mechanisms as well as further activation of HOX genes. This results in differentiation
(Diff), which appears to follow a standard hECC pattern through downregulation of Oct4, Sox2 and Nanog gene expression
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Our data feed into an on-going discussion about the
relationship between TLR signalling and pluripotency. ESCs
express TLRs and can respond to microbial products, a
response that can enhance myeloid-lineage differentiation.30
TLR ligands are reportedly secreted by murine ESCs
(mESCs)31 but not hESCs.32 There is also clearly an overlap
between TLR signalling and RA. For example, RA-Inducible
gene 1 is an established viral pattern recognition receptor in
innate immunity,33 which can be stimulated by bacterial wall
component lipopolysaccharide (LPS),34 is necessary for
bacterial phagocytosis in macrophages, and is required for
RA differentiation of myeloid cells.35 MyD8817 and Toll36 were
originally identified as a modulator of myeloid cell
differentiation and a developmental regulator in Drosophila,
respectively, roles apparently distinct from immunity. MyD88
has been shown to be expressed and functional in some
mESC lines37 as well as, for example, mesenchymal38 and
haematopoietic39 adult stem cells. In the MyD88 mechanism
we have described here, upregulation of TLR3 may result in
chromatin remodelling to facilitate changes in expression of
key differentiation genes, in a similar manner to that underlying
increased iPS efficiency in TLR3 expressing cells.40,41
In addition, there is no clear evidence that innate immunity is
required by or functional in such early stages of embryogen-
esis (inner cell mass cells within the blastocyst). As such, our
data support a broader view of the role of TLR signalling,
where the pathway can respond to different stimuli at different
developmental stages. In this regard, TLR signalling may
serve to regulate the stem cell or cancer stem cell (CSC) niche
through the regulated secretion of specific proteins by the cell.
Tumour-initiation is a property of self-renewing CSCs such
as hECCs, which is lost during differentiation.42 In the
developing tumour, CSCs that persist in the SR state while
other CSCs differentiate are, therefore, clear clinical targets.
Global targeting of CSCs via forced-differentiation treatments
using drugs such as RA has been largely inefficient in the
clinic, apart from in specific patients with specific
malignancies,43-45 which indicates the importance of better
understanding CSC differentiation resistance. Although the
mechanisms through which certain CSCs resist differentiation
are unknown, it is likely to involve regulation of growth factors
in specific SR niches within the tumour. For example, in
ovarian CSCs, MyD88-dependent TLR signalling has been
shown to create a microenvironment that facilitates self-
renewal.46 As such, it is interesting that we have highlighted a
role for MyD88, a key determinant of growth factor secretion
into the niche, in differentiation resistance. We have shown
that hECC nullipotency, an extreme model of differentiation
resistance, is owing to MyD88 acting as a ‘Differentiation
Gatekeeper’ that must be compromised to facilitate differ-
entiation. We have previously shown that 2102Ep nullipotency
can be surpassed by forced-differentiation via knockdown of
Sox2.47 As such, it appears that maintained MyD88 expres-
sion in 2102Ep cells is owing to a defect in the MyD88
downregulation mechanism, the search for which will con-
tinue. It is possible that similar differentiation gatekeepers exist
in other malignancies. If so, our data suggest that a two-tier
strategy involving a differentiation morphogen such as RA in
combination with targeting of a specific differentiation reg-
ulator may be more successful than treatment with a single
agent. Although the MyD88 PepInh approach employed here
was highly efficient, it is not clear whether MyD88, as a key
regulator of immunity, could be inhibited in the clinic without
detrimental side effects for the patient. However, if essential
differentiation regulators can be identified in other malignan-
cies, their targeting may synergistically enhance the effects of
differentiation treatments.
Materials and Methods
Cell culture, transfections and differentiation protocols. Cell
culture, siRNA transfection and RA differentiation were performed as previously
described.47,48 MyD88 overexpression was achieved by transfection of a constitutive
expression plasmid (IOH9958-pDEST26, IMAgene, Berlin, Germany) for 3 days.
Table 2 Selected genes expressed by 2102Ep cells treated with MyD88
compared with control PepInh, control PepInh compared with control PepInh
+RA, and MyD88 PepInh compared with SSEA4Neg cells
SSEA4Neg versus MyD88 PepInh
Gene name Fold change P-value
Pluripotency
Nanog −7.2 1.89E− 05
Sox2 −7.2 2.89E− 06
Oct4 −1.8 0.01
Toll-like receptors
TLR7 24 6.20E− 07
TLR3 3.2 1.57E− 05
TLR4 −2.5 0.00055
RA signalling
STRA6 2.3 0.00017
CRABP2 2.2 0.00015
RARB 8.8 1.68−E06
RARA 2 0.00038
RARRES3 2.3 6.60E− 06
RAI 14 2.6 3.60E− 05
HOX genes
HOXA1 6.8 3.08E− 06
HOXA2 3.7 2.77E− 05
HOXA3 2.4 0.0015
HOXA5 3.4 1.77E− 05
HOXB1 4.2 9.53E− 06
HOXB3 7.2 2.71E− 06
HOXB4 4.9 2.93E− 05
HOXB5 3.3 3.04E− 05
HOXC8 2.4 0.0023
HOXC13 2.9 0.00015
Interferon-stimulated genes (ISGs)
IFI44L −85.4043618 2.08E− 11
IFIT3 −35.59805019 1.55E− 09
IFIH1 −31.50036308 1.71E− 09
IFI44 −25.502419 3.92E− 09
IFI6 −25.27572766 2.85E− 10
IFIT1 −17.39771836 2.24E− 09
IFIT2 −16.18933034 1.87E− 09
IFI27 −11.32773296 1.29E− 07
IRF9 −8.488694247 1.08E− 08
GBP2 −8.195717684 1.21E− 07
IFI35 −4.23411297 2.23E− 07
IRF1 −3.98565266 1.64E− 07
IFIT5 −3.970552695 1.97E− 06
IRF2BP2 −2.692853863 2.18E− 06
IRF7 −2.120580336 1.9E−05
IFI16 −2.111790274 1.11E− 05
JAK-STAT signalling
STAT1 4.7 3.93E− 08
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MyD88 inhibition was achieved by addition of 5 μM MyD88 Peptide Inhibitor
(PepInh, Invivogen, San Diego, CA, USA) or the supplied control PepInh to 50-
56 000 (24-well plate) or 168 000 (six-well plate) cells/well. After an initial 6 h
treatment, PepInh was refreshed and cells cultured overnight, after which RA
(10− 5 M) and PepInh were added together with media refreshed daily. Lineage
differentiation assays were carried out similarly, with the addition of growth factor
solutions supplied in specific StemXvivo Mesoderm, Ectoderm or Endoerm kits
(R&D Systems, Abingdon, UK) instead of RA, and using manufacturer’s instructions.
Specific medias were refreshed daily for 6 days.
Quantitative ELISAs. MyD88 inhibition was assayed by treating 56 000 cells
with MyD88 or control PepInh for 24 h and then with IL-1β (30 ng/ml, InvivoGen),
which can only act MyD88-dependently, for 30 min. Activation of MyD88-dependent
signalling was detected as the presence of phosphorylated-I-κBα using the
‘PhosphoTracer I-κBα Total ELISA’ kit (Abcam, Cambridge, UK) as per
manufacturer’s instructions. Alkaline Phosphatase expression was quantified using
the ‘Quantitative Alkaline Phosphatase ES Characterisation Kit’ (Millipore,
Nottingham, UK) as per manufacturer’s instructions.
Conditioned media work. UndiffCon media was prepared by collecting
media from NTera2 cells daily for 7 days. For DiffCon media, NTera2 cells were RA
differentiated for 7 days. These differentiated cells were then cultured for a further
7 days in –RA media, which was collected and refreshed daily. Conditioned media
was pooled and filtered using a 0.2 μm polyethersulfone filter. For conditioned
media treatments, 2 ml of conditioned media was added to 180 000 cells in six-well
plates and replaced daily.
Flow cytometry/FACS. For each sample, after dissociation using EDTA
(1 mM), 1 million cells were assayed with PE-conjugated mouse IgG3 anti-SSEA4
antibody (MC-813-70, R&D Systems), using PE-conjugated mouse IgG3 (133316,
R&D Systems) and unstained samples as isotype and autoflourescence,
respectively. Flow cytometry was performed on a Cyan ADP Flow Cytometer
(Beckman Coulter, High Wycombe, UK). Samples were excited using a 488 nm
laser and detected between 575/25 nm. Doublets were excluded using the pulse
width parameter and dead cells were excluded using propidium iodide staining
(Invitrogen; Excited= 488 nm; detected= 680/30 nm). FACS was performed using
the MoFlo XDP (Beckman Coulter) and FACSAria Fusion cell sorters (BD
Bioscience, Oxford, UK). Flow cytometry was carried out at the TCD facilities in the
Institute of Molecular Medicine (IMM), St James’s Hospital, Dublin 8 and the Trinity
Biomedical Sciences Institute (TBSI), Pearse Street, Dublin 8.
Western blot, qPCR, gene and protein array analysis. Western blot
analysis was carried out as previously described 47; Antibodies; MyD88: #4283 Cell
Signalling Technologies, Gapdh: Ab8245, Abcam). qPCR was carried out as
previously described.12 RNA was isolated using the mirVANA kit (Ambion, Waltham,
MA, USA). Three- day differentiation experiment gene expression array analysis
was carried out using HGU133 Plus2 GeneChips. A total of 1 μg RNA was prepared
using the ‘One-Cycle Eukaryotic Target Labelling’ protocol and assayed on HGU133
Plus2 GeneChips (All Affymetrix, Waltham, MA, USA) as per manufacturer’s
instructions. All other gene expression array analysis was carried out using
Affymetrix GeneChip HuGene 2.0 ST arrays. Final 150 ng samples were prepared
using the ‘WT Plus reagent Kit’, and prepared samples fragmented and labelled
using the ‘WT Labelling Kit’ (Affymetrix) as per manufacturer’s instructions. Post
hybridisation, all samples were washed using a fluidics station 450 and scanned
using a GeneChip Scanner 3000 (both Affymetrix) as per manufacturer’s
instructions. Pre-processing and analysis of gene expression array data was
performed as described in Supplementary Methods. For protein arrays, conditioned
media samples were concentrated using Amicon Ultracel 3 kDa spin filters
(Millipore) and assayed using Quantibody Human Chemokine and Cytokine arrays
(RayBioTech, Norcross, GA, USA) as per manufacturer’s instructions.
Statistical analysis. Statistical analysis of flow cytometry, protein array and
qPCR data was carried out using the student’s two-tailed t-test. Data is presented
as the mean of three biological replicates± S.E.M. GraphPad prism 6 was used to
generate P-values.
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